BE874937A - Glycoproteines-hgi capables de stimuler la proliferation et la differentiation de granulocyte humaine, leur procede de preparation et medicaments contre la leucopenie en contenant - Google Patents

Glycoproteines-hgi capables de stimuler la proliferation et la differentiation de granulocyte humaine, leur procede de preparation et medicaments contre la leucopenie en contenant

Info

Publication number
BE874937A
BE874937A BE0/194089A BE194089A BE874937A BE 874937 A BE874937 A BE 874937A BE 0/194089 A BE0/194089 A BE 0/194089A BE 194089 A BE194089 A BE 194089A BE 874937 A BE874937 A BE 874937A
Authority
BE
Belgium
Prior art keywords
leucopenia
hgi
glycoproteins
stimulating
proliferation
Prior art date
Application number
BE0/194089A
Other languages
English (en)
Original Assignee
Morinaga Milk Industry Co Ltd
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morinaga Milk Industry Co Ltd, Green Cross Corp filed Critical Morinaga Milk Industry Co Ltd
Publication of BE874937A publication Critical patent/BE874937A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/22—Urine; Urinary tract, e.g. kidney or bladder; Intraglomerular mesangial cells; Renal mesenchymal cells; Adrenal gland
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/834—Urine; urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
BE0/194089A 1978-03-20 1979-03-19 Glycoproteines-hgi capables de stimuler la proliferation et la differentiation de granulocyte humaine, leur procede de preparation et medicaments contre la leucopenie en contenant BE874937A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP53031999A JPS6030291B2 (ja) 1978-03-20 1978-03-20 人顆粒球の分化増殖を促進するｈｇｉ糖蛋白質、ｈｇｉ糖蛋白質の製造法及びｈｇｉ糖蛋白質を含有する白血球減少症治療剤

Publications (1)

Publication Number Publication Date
BE874937A true BE874937A (fr) 1979-07-16

Family

ID=12346597

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/194089A BE874937A (fr) 1978-03-20 1979-03-19 Glycoproteines-hgi capables de stimuler la proliferation et la differentiation de granulocyte humaine, leur procede de preparation et medicaments contre la leucopenie en contenant

Country Status (6)

Country Link
US (1) US4275056A (fr)
JP (1) JPS6030291B2 (fr)
BE (1) BE874937A (fr)
CA (1) CA1120468A (fr)
SU (1) SU1431691A3 (fr)
ZA (1) ZA791282B (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4342828A (en) * 1979-07-20 1982-08-03 Morinaga Milk Industry Co., Ltd. Method for producing substance capable of stimulating differentiation and proliferation of human granulopoietic stem cells
US4481137A (en) * 1982-02-26 1984-11-06 Mochida Pharmaceutical Co., Ltd. Glycoproteins and processes for their production
JPS59137417A (ja) * 1983-01-28 1984-08-07 Morinaga Milk Ind Co Ltd 人尿由来コロニ−形成刺激因子及びカリクレインの製造法
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
JPS60209526A (ja) * 1984-04-04 1985-10-22 Denki Kagaku Kogyo Kk 高純度ｃｓｆの製造方法
US5573930A (en) * 1985-02-05 1996-11-12 Cetus Oncology Corporation DNA encoding various forms of colony stimulating factor-1
US5556620A (en) * 1985-02-05 1996-09-17 Cetus Oncology Corporation Use of recombinant colony stimulating factor-1 to enhance wound healing
US6156300A (en) * 1985-02-05 2000-12-05 Chiron Corporation Point mutants of N∇2 CSF-1 and carboxy truncated fragments thereof
US4847201A (en) * 1985-02-05 1989-07-11 Cetus Corporation DNA encoding for CSF-1 and accompanying recombinant systems
US5104650A (en) * 1985-02-05 1992-04-14 Cetus Corporation Uses of recombinant colony stimulating factor-1
AU594045B2 (en) * 1985-02-05 1990-03-01 Chiron Corporation Recombinant colony stimulating factor-1
US5837229A (en) * 1985-02-05 1998-11-17 Chiron Corporation Uses of recombinant colony stimulating factor-1
US5792450A (en) * 1985-02-05 1998-08-11 Chiron Corporation Purified human CSF-1
US5422105A (en) * 1985-02-05 1995-06-06 Cetus Oncology Corporation Use of recombinant colony stimulating factor 1
US6146851A (en) * 1985-02-05 2000-11-14 Chiron Corporation DNA encoding NV2 (long form) and carboxy truncated fragments thereof
JPH0753667B2 (ja) * 1985-08-09 1995-06-07 新技術開発事業団 骨髄移植療法補助剤
JPH0618778B2 (ja) * 1985-10-04 1994-03-16 中外製薬株式会社 白血球減少症治療剤
JPH0618779B2 (ja) * 1986-01-22 1994-03-16 中外製薬株式会社 造血機能回復促進剤
DE3613166A1 (de) * 1986-04-18 1987-10-29 Basf Ag Verwendung von tnf zur herstellung von arzneimitteln
DE3613167A1 (de) * 1986-04-18 1987-10-29 Basf Ag Verwendung von tnf zur herstellung von arzneimitteln
JP2577744B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
JP2629000B2 (ja) * 1986-07-18 1997-07-09 中外製薬株式会社 安定な顆粒球コロニー刺激因子含有製剤
JP2577743B2 (ja) * 1986-07-18 1997-02-05 中外製薬株式会社 安定な顆粒球コロニ−刺激因子含有製剤
JPH0694479B2 (ja) * 1986-10-31 1994-11-24 電気化学工業株式会社 ヒト尿由来ｃｓｆ及びその製法
FR2607344B1 (fr) * 1986-11-21 1994-04-29 Nexo Distribution Dispositif de traitement d'un signal electrique audiofrequence
EP0276551B1 (fr) * 1986-12-07 1992-03-18 Morinaga Milk Industry Co., Ltd. Facteur stimulant de colonie et sa méthode de préparation
JPH0611705B2 (ja) * 1988-02-10 1994-02-16 新技術事業団 血小板減少症治療剤
JP2657113B2 (ja) * 1989-10-16 1997-09-24 アムジエン・インコーポレーテツド 幹細胞因子
US7144731B2 (en) * 1989-10-16 2006-12-05 Amgen Inc. SCF antibody compositions and methods of using the same
US20040181044A1 (en) * 1989-10-16 2004-09-16 Zsebo Krisztina M. Method of stimulating growth of epithelial cells by administering stem cell factor
US6852313B1 (en) 1989-10-16 2005-02-08 Amgen Inc. Method of stimulating growth of melanocyte cells by administering stem cell factor
EP1617936B1 (fr) * 2003-02-19 2009-11-18 Natrix Separations Inc. Materiaux composites porteur de gels poreux
WO2005097304A1 (fr) * 2004-04-08 2005-10-20 Mcmaster University Empilements de membranes
JP4806401B2 (ja) 2004-06-07 2011-11-02 ナトリックス セパレイションズ インコーポレーテッド 支持型多孔質ゲルを含む安定な複合材料
JP4618485B2 (ja) * 2004-08-27 2011-01-26 アイシン精機株式会社 モータ用ブラシ材料の製造方法
MX2009002576A (es) * 2006-09-08 2009-03-20 Wyeth Corp Lavado de arginina en purificacion de proteina utilizando cromatografia de afinidad.
WO2010027955A2 (fr) 2008-09-02 2010-03-11 Natrix Separations Inc. Membranes de chromatographie, dispositifs les contenant et procédés d’utilisation associés
AU2010317563B2 (en) * 2009-11-13 2014-06-19 Merck Millipore Ltd. Hydrophobic interaction chromatography membranes, and methods of use thereof
ES2968249T3 (es) 2011-05-17 2024-05-08 Merck Millipore Ltd Dispositivo con membranas tubulares en capas para cromatografía

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4178285A (en) * 1978-12-20 1979-12-11 Felts James M Separation of active α1 -acid glycoprotein and utilization in the lipoprotein lipase enzyme system

Also Published As

Publication number Publication date
US4275056A (en) 1981-06-23
CA1120468A (fr) 1982-03-23
ZA791282B (en) 1980-03-26
JPS54140707A (en) 1979-11-01
JPS6030291B2 (ja) 1985-07-16
SU1431691A3 (ru) 1988-10-15

Similar Documents

Publication Publication Date Title
BE874937A (fr) Glycoproteines-hgi capables de stimuler la proliferation et la differentiation de granulocyte humaine, leur procede de preparation et medicaments contre la leucopenie en contenant
BE895708A (fr) Urees et thio-urees substituees, leur procede de preparation et leur application therapeutique comme medicaments anti-atherosclereux
BE860727A (fr) Nouveaux benzamides trans-n-(2-aminocycloaliphatiques), leur procede de preparation et medicament les contenant
BE878723A (fr) Derives de 4-anilinoquinazoline, leur procede de preparation et leur application en therapeutique
FR2471968B1 (fr) Ethers basiques, leur procede de preparation et compositions pharmaceutiques les contenant
BE865015A (fr) Pseudotrisaccharides, leur procede de preparation et medicament les contenant
BE885385A (fr) Derives de d-6-n-propylergolines, leur procede de preparation et compositions pharmaceutiques en contenant
FR2521134B1 (fr) Urees et thio-urees substituees, leur procede de preparation et leur application therapeutique comme medicaments anti-atherosclereux
BE794742A (fr) Nouveaux di-n-oxydes (1,4) de benzo-1,2,4-triazine, leur procede de preparation et leur application comme medicaments et additifs de nutrition
BE885156A (fr) Psoralenes, leur procede de preparation et compositions pharmaceutiques les contenant
BE865601A (fr) Medicaments contenant des alcenylxanthines et leur procede de preparation
BE868943A (fr) Nouveaux 3-indolyl-tertiobutylaminopropanols, leur procede de production et medicament les contenant
BE885196A (fr) Genes de la proinsuline humaine et de prepoinsuline humaine, leur procede de preparation et leurs applications
BE876297A (fr) Nouveaux derives de 4-amino-2-piperidino-quinazoline, leur procede de production et medicament les contenant
BE875106A (fr) Medicaments anticomplementaires en partie antinephretiques, de type soya-sapogenol b et leur procede de preparation
BE872484A (fr) 1-phenyl-2-pyrrolidin-2-yl-ethanols substitues, leur procede de preparation, leurs applications et medicaments les contenant
BE884083A (fr) Nouveaux oxime-ethers, leur procede de preparation et compositions pharmaceutiques les contenant
FR2292477A1 (fr) Derives de 1-amidoalkyl-4-sulfonyl-piperazine, leur procede d'obtention et medicaments contenant lesdits derives
BE831421A (fr) Nouvelles phenylisothiourees substituees, leur procede de preparation et medicament les contenant
BE864644A (fr) Nouveaux derives de prostaglandines, leur procede de preparation et medicaments les contenant
BE863618A (fr) Nouveaux derives semi-synthetiques de 4"-amino-oleandomycine, leur procede de preparation et medicament les contenant
BE861697A (fr) Nouveaux antibiotiques polycycliques, leur procede de preparation et medicament les contenant
BE825245A (fr) Nouvelles 2-amino-6-dialkylaminodihydropyridines leur procede de preparation et medicament les contenant
BE843115A (fr) Compositions pharmaceutiques contenant de la debrycine heterocolloidale et leur procede de preparation
BE805210A (fr) Nouveaux amides d'acides imidazoiylacetiques, leur procede de preparation et medicaments les contenant

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: THE GREEN CROSS CORP.

Effective date: 19950331

Owner name: MORINAGA MILK INDUSTRY CO. LTD

Effective date: 19950331